- Home
- RLAY vs UROY Comparison
RLAY vs UROY Comparison
Compare RLAY & UROY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLAY
- UROY
- Stock Information
- Founded
- RLAY 2015
- UROY 2017
- Country
- RLAY United States
- UROY Canada
- Employees
- RLAY N/A
- UROY N/A
- Industry
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- UROY
- Sector
- RLAY Health Care
- UROY
- Exchange
- RLAY Nasdaq
- UROY Nasdaq
- Market Cap
- RLAY 803.4M
- UROY 649.5M
- IPO Year
- RLAY 2020
- UROY N/A
- Fundamental
- Price
- RLAY $6.72
- UROY $3.82
- Analyst Decision
- RLAY Strong Buy
- UROY Strong Buy
- Analyst Count
- RLAY 8
- UROY 1
- Target Price
- RLAY $17.25
- UROY $4.50
- AVG Volume (30 Days)
- RLAY 2.0M
- UROY 6.9M
- Earning Date
- RLAY 11-06-2025
- UROY 12-11-2025
- Dividend Yield
- RLAY N/A
- UROY N/A
- EPS Growth
- RLAY N/A
- UROY N/A
- EPS
- RLAY N/A
- UROY N/A
- Revenue
- RLAY $8,355,000.00
- UROY $35,266,447.00
- Revenue This Year
- RLAY $27.30
- UROY $195.97
- Revenue Next Year
- RLAY $7.43
- UROY N/A
- P/E Ratio
- RLAY N/A
- UROY N/A
- Revenue Growth
- RLAY N/A
- UROY 14.29
- 52 Week Low
- RLAY $1.78
- UROY $1.43
- 52 Week High
- RLAY $7.64
- UROY $5.37
- Technical
- Relative Strength Index (RSI)
- RLAY 55.13
- UROY 43.17
- Support Level
- RLAY $6.64
- UROY $3.87
- Resistance Level
- RLAY $7.42
- UROY $5.02
- Average True Range (ATR)
- RLAY 0.43
- UROY 0.34
- MACD
- RLAY -0.11
- UROY -0.06
- Stochastic Oscillator
- RLAY 30.97
- UROY 11.65
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
About UROY Uranium Royalty Corp.
Uranium Royalty Corp is focused on gaining exposure to uranium prices by making investments in uranium interests, including royalties, streams, debt and equity investments in uranium companies, and through holdings of physical uranium. The company operates in a single segment that is acquiring and assembling a portfolio of royalties, investing in companies with exposure to uranium and physical uranium. The Company also engages in the purchase and sale of physical uranium.